2. Search Result
Search Result
Results for "

G_s proteins

" in MedChemExpress (MCE) Product Catalog:

38

Inhibitors & Agonists

1

Biochemical Assay Reagents

5

Peptides

3

Inhibitory Antibodies

2

Natural
Products

4

Isotope-Labeled Compounds

Targets Recommended:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-111964
    Lenacapavir
    Maximum Cited Publications
    19 Publications Verification

    GS-6207

    		 HIV Infection
    Lenacapavir (GS-6207) is an HIV-1 capsid inhibitor. Lenacapavir binds to the interface between capsid hexamers and CA monomers, disrupts capsid assembly and viral maturation, inhibits nuclear translocation of HIV-1 DNA, interferes with CA-mediated protein-protein interactions, reduces the formation of 2-LTR circles and pre-integration proviruses, induces aberrant capsids, and decreases the production of mature HIV-1. Lenacapavir exhibits activity against a variety of HIV-1 subtypes and clinical isolates. Lenacapavir is applicable to research related to human immunodeficiency virus type 1 (HIV-1) infection .
    Lenacapavir
  • HY-112461A
    NF449 octasodium
    4 Publications Verification

    		 P2X Receptor Cardiovascular Disease
    NF449 octasodium is a highly potent P2X1 receptor antagonist, with IC50s of 0.28, 0.69, and 120 nM for rP2X1, rP2X1+5, P2X2+3, respectively. NF449 octasodium is a Gsα-selective G Protein antagonist. NF449 octasodium suppresses the rate of GTP[γS] binding to Gsα-s, inhibits the stimulation of adenylyl cyclase activity, and blocks the coupling of β-adrenergic receptors to Gs .
    NF449 octasodium
  • HY-12530
    Velpatasvir
    5+ Cited Publications

    GS-5816

    		 HCV SARS-CoV Infection Inflammation/Immunology Cancer
    Velpatasvir (VEL, GS-5816) is a novel pan-genotypic hepatitis C virus (HCV) nonstructural protein 5A (NS5A) inhibitor with activity against genotype 1 (GT1) to GT6 HCV replicons. Velpatasvir is also a SARS-CoV 3CL pro inhibitor with an IC50 of 2.16 μM .
    Velpatasvir
  • HY-138407
    Evixapodlin

    GS-4224; PD-1/PD-L1-IN 7

    		 PD-1/PD-L1 HBV Infection Cancer
    Evixapodlin (GS-4224) is a human PD-1/PD-L1 protein/protein interaction inhibitor with an IC50 of 0.213 nM. Evixapodlin has anticancer and antiviral functions .
    Evixapodlin
  • HY-137683A
    Guanosine 5'-O-2-thiodiphosphate trisodium

    GDPβS trisodium

    		 Adenylate Cyclase Cardiovascular Disease
    Guanosine 5'-O-(2-thiodiphosphate) trisodium (GDPβS trisodium) is a non-hydrolyzable derivative of GDP. Guanosine 5'-O-(2-thiodiphosphate) trisodium acts as an inhibitor of adenylyl cyclase (AC) with a Ki value of 600 nM. In the absence of glutamic-pyruvic transaminase (GPT) in cerebral cortex membranes of rodent models, Guanosine 5'-O-(2-thiodiphosphate) trisodium partially activates AC with an EC50 of 400 nM. Guanosine 5'-O-(2-thiodiphosphate) trisodium prevents norepinephrine-induced nitric oxide release in ventricular myocytes .
    Guanosine 5'-O-2-thiodiphosphate trisodium
  • HY-P99047
    Simtuzumab

    AB 0024; GS 6624

    		 Monoamine Oxidase Cardiovascular Disease Inflammation/Immunology
    Simtuzumab (AB 0024; GS 6624) is a monoclonal antibody directed against Lysyl oxidase like-2 (LOXL2). Simtuzumab non-competitively blocks collagen cross-linking, reduces LOXL2 protein expression and attenuates extracellular matrix changes. Simtuzumab reduces myocardial fibrosis and prevents cardiac dysfunction. Simtuzumab lowers Myh7 and Nppa gene expression, reduces contraction heterogeneity, and cuts COL1A1 deposition. Simtuzumab can be used for the research of LMNA mutation-induced dilated cardiomyopathy, idiopathic pulmonary fibrosis, and primary sclerosing cholangitis .
    Simtuzumab
  • HY-112461
    NF449

    		P2X Receptor Cardiovascular Disease
    NF449 is a highly potent P2X1 receptor antagonist, with IC50s of 0.28, 0.69, and 120 nM for rP2X1, rP2X1+5, P2X2+3, respectively. NF449 is a Gsα-selective G Protein antagonist. NF449 suppresses the rate of GTP[γS] binding to Gsα-s, inhibits the stimulation of adenylyl cyclase activity, and blocks the coupling of β-adrenergic receptors to Gs .
    NF449
  • HY-111964A
    Lenacapavir sodium
    Maximum Cited Publications
    19 Publications Verification

    GS-6207 sodium

    		 HIV Infection
    Lenacapavir (GS-6207) sodium is an HIV-1 capsid inhibitor. Lenacapavir sodium binds to the interface between capsid hexamers and CA monomers, disrupts capsid assembly and viral maturation, inhibits nuclear translocation of HIV-1 DNA, interferes with CA-mediated protein-protein interactions, reduces the formation of 2-LTR circles and pre-integration proviruses, induces aberrant capsids, and decreases the production of mature HIV-1. Lenacapavir sodium exhibits activity against a variety of HIV-1 subtypes and clinical isolates. Lenacapavir sodium is applicable to research related to human immunodeficiency virus type 1 (HIV-1) infection .
    Lenacapavir sodium
  • HY-123622
    CYMAL-5, 98% (TLC)

    		Biochemical Assay Reagents Others
    CYMAL-5, 98% (TLC) is a cycloalkyl aliphatic saccharide. CYMAL-5, 98% (TLC) is a glycosidic surfactant (GS) with a chiral maltose polar head group and a cyclohexyl-pentyl hydrophobic tail. CYMAL-5, 98% (TLC) is a non-ionic detergent that has a tenfold lower critical micelle concentration (CMC) in comparison with OG, and has previously been used for membrane protein extraction or crystallization of membrane proteins for X-ray crystallographic studies .
    CYMAL-5, 98% (TLC)
  • HY-P3570
    Adipokinetic hormone II (Locusta migratoria)

    Lom-AKH-II

    		 Endogenous Metabolite Metabolic Disease
    Adipokinetic hormone II (Locusta migratoria) (Lom-AKH-II) is a insect adipokinetic hormone (AKH), enhances fat body cAMP levels in vitro. Insect adipokinetic hormones (AKHs) controls flight-directed mobilization of carbohydrate and lipid from fat body stores, which depends on AKH receptor(s) coupling to cAMP formation and glycogen phosphorylase activation via the stimulatory guanine nucleotide-binding protein (Gs) .
    Adipokinetic hormone II (Locusta migratoria)
  • HY-N0927
    (-)-Isocorypalmine

    Tetrahydrocolumbamine; (S)-Tetrahydrocolumbamine

    		 Dopamine Receptor Others Neurological Disease
    (-)-Isocorypalmine (Tetrahydrocolumbamine; (S)-Tetrahydrocolumbamine) is a dopamine receptor ligand and modulator capable of crossing the blood-brain barrier. (-)-Isocorypalmine exhibits receptor selectivity, acting as a partial agonist of dopamine D1 and D5 receptors (coupled via Gs proteins), as well as an antagonist of D2, D3 and D4 receptors (by blocking Gi protein-mediated signaling). (-)-Isocorypalmine shows no significant binding to various non-dopamine receptors, ion channels and transporters. (-)-Isocorypalmine is metabolically stable in vivo, effectively inhibits spontaneous and cocaine-induced hyperlocomotion, sensitization and conditioned place preference in mice, and does not induce addictive place preference when administered alone. (-)-Isocorypalmine can be used in addiction research .
    (-)-Isocorypalmine
  • HY-134557
    GS87

    		GSK-3 Cancer
    GS87 is a highly specific and potent GSK3 inhibitor with IC50s of 415nM and 521nM for GSK3α and GSK3β, respectively. GS87 induces differentiation of acute myeloid leukemia (AML) cell lines by effectively activating GSK3-dependent signaling components including MAPK signaling. GS87 modulates key GSK3 target proteins involved in cell proliferation and differentiation more effectively than Lithium and SB415285 (SB). GS87 has the potential for acting as a differentiation agent for non-promyelocytic AML research .
    GS87
  • HY-12530R
    Velpatasvir (Standard)

    GS-5816 (Standard)

    		 Reference Standards HCV SARS-CoV Infection Inflammation/Immunology Cancer
    Velpatasvir (Standard) is the analytical standard of Velpatasvir. This product is intended for research and analytical applications. Velpatasvir (VEL, GS-5816) is a novel pan-genotypic hepatitis C virus (HCV) nonstructural protein 5A (NS5A) inhibitor with activity against genotype 1 (GT1) to GT6 HCV replicons. Velpatasvir is also a SARS-CoV 3CL pro inhibitor with an IC50 of 2.16 μM .
    Velpatasvir (Standard)
  • HY-P3572
    Adipokinetic hormone I (Locusta migratoria)

    Lom-AKH-I

    		 Endogenous Metabolite Endocrinology
    Adipokinetic hormone I (Locusta migratoria) (Lom-AKH-I) is a insect adipokinetic hormone (AKH), enhances fat body cAMP levels in vitro. Insect adipokinetic hormones (AKHs) controls flight-directed mobilization of carbohydrate and lipid from fat body stores, which depends on AKH receptor(s) coupling to cAMP formation and glycogen phosphorylase activation via the stimulatory guanine nucleotide-binding protein (Gs) .
    Adipokinetic hormone I (Locusta migratoria)
  • HY-P10365
    VPM-p15

    		Adhesion G Protein-coupled Receptors (AGPCRs) Others
    Vmm-p15 is a peptide agonist optimized for the adhesion G protein-coupled receptor GPR64 (also known as ADGRG2 or HE6). The affinity of VPM-p15 with GPR64 is significantly higher than that of the original p15 peptide. The cAMP level induced by VMM-P15 increased significantly, activated GPR64, and triggered downstream Gs, Gq, and G12/13 signaling. VPM-p15 can be used to study the activation mechanism of adherent GPCR family members .
    VPM-p15
  • HY-120159
    GS-493

    		SHP2 SHP1 Phosphatase Cancer
    GS-493 is a selective protein tyrosine phosphatase SHP2 (PTPN11) inhibitor with an IC50 of 71 nM. GS-493 is 29- and 45-fold more active toward SHP2 than related SHP1 and PTP1B. GS-493 blocks cellular motility and growth of cancer cells. Antitumor activity .
    GS-493
  • HY-141495
    (Rac)-Razpipadon
    1 Publications Verification

    PW0464

    		 Dopamine Receptor Neurological Disease
    PW0464, a nanomolar potent complete G protein biased ligand, is a noncatechol D1R agonist, with an EC50 of 5.8 nM (Gs-cAMP) .
    (Rac)-Razpipadon
  • HY-16275
    Nivocasan

    GS 9450; LB-84451

    		 Caspase Interleukin Related Inflammation/Immunology
    Nivocasan (GS 9450; LB-84451) is a pan-caspase inhibitor that irreversibly arrests caspase-1 activity and inhibits that of caspase-8. Nivocasan inhibits IL-1β cleavage and blocks osteoclast differentiation. Nivocasan inhibits the protein expression of NFATc1 and CSTK .
    Nivocasan
  • HY-12530S1
    Velpatasvir-d3

    GS-5816-d33

    		 Isotope-Labeled Compounds SARS-CoV HCV Infection Inflammation/Immunology Cancer
    Velpatasvir-d3 (GS-5816-d3) is deuterium labeled Velpatasvir. Velpatasvir (VEL, GS-5816) is a novel pan-genotypic hepatitis C virus (HCV) nonstructural protein 5A (NS5A) inhibitor with activity against genotype 1 (GT1) to GT6 HCV replicons. Velpatasvir is also a SARS-CoV 3CL pro inhibitor with an IC50 of 2.16 μM .
    Velpatasvir-d3
  • HY-P1376
    G-Protein antagonist peptide

    		mAChR Adrenergic Receptor Endocrinology
    G-Protein antagonist peptide is the substance P-related peptide that inhibits binding of G proteins to their receptors. G-Protein antagonist peptide competitively and reversibly inhibits M2 muscarinic receptor activation of Gi or Go and inhibits Gs activation by β-adrenoceptors.
    G-Protein antagonist peptide
  • HY-16773
    Vedroprevir

    GS-9451

    		 HCV Protease BCRP P-glycoprotein Infection
    Vedroprevir (GS-9451) is an inhibitor for HCV NS3/4A protease with an IC50 of 3.2 nM. Vedroprevir is also an inhibitor for breast cancer resistant protein (BCRP) with an IC50 of 1.4 μM. Vedroprevir inhibits P-gp, MRP1 and MRP2 with IC50 of 34, 14.9 and 12 μM, respectively. Vedroprevir exhibits good pharmacokinetic characteristics in rats and dogs .
    Vedroprevir
  • HY-P991479
    Amtabafusp alfa

    GS-8588

    		 HIV CD3 Infection
    Amtabafusp alfa (GS-8588) is an envelope-targeting bispecific T-cell engager for HIV treatment. Amtabafusp alfa redirects effector T cells by binding to CD3 via a humanized anti-CD3 Fab domain and to HIV envelope proteins via an engineered CD4 domain 1 variant. Amtabafusp alfa exhibits potent, broad-spectrum activity against a variety of HIV isolates and specifically kills HIV-infected cells. Amtabafusp alfa can be used for research on HIV infection .
    Amtabafusp alfa
  • HY-14308
    GS-9851

    PSI-7851

    		 Endogenous Metabolite Infection
    GS-9851 (PSI-7851) is a HCV nonstructural protein 5B (NS5B) inhibitor with potential activity for the study of HCV infection. GS-9851 shows good tolerability with initial HCV genotype 1 infection. GS-9851 is rapidly cleared from the body with a half-life of approximately 1 hour .
    GS-9851
  • HY-12530S3
    Velpatasvir-13C,d3

    GS-5816-13C,d3

    		 Isotope-Labeled Compounds Infection Inflammation/Immunology Cancer
    Velpatasvir- 13C,d3 (GS-5816- 13C,d3) is 13C and deuterium labeled Velpatasvir. Velpatasvir (VEL, GS-5816) is a novel pan-genotypic hepatitis C virus (HCV) nonstructural protein 5A (NS5A) inhibitor with activity against genotype 1 (GT1) to GT6 HCV replicons. Velpatasvir is also a SARS-CoV 3CL pro inhibitor with an IC50 of 2.16 μM .
    Velpatasvir-13C,d3
  • HY-16750
    Radalbuvir

    GS-9669

    		 DNA/RNA Synthesis HCV Infection
    Radalbuvir (GS-9669) is a non-nucleoside inhibitor of nonstructural protein 5B (NS5B) RNA-dependent RNA polymerase (RdRp). Radalbuvir shows strong anti-HCV potency (GT1a intrinsic EC50 = 2.9 nM, GT1b EC50 = 6 nM) .
    Radalbuvir
  • HY-W749691
    (S)-Velpatasvir-13c,d3

    (S)-GS-5816-13C,d3

    		 Isotope-Labeled Compounds SARS-CoV HCV Infection Inflammation/Immunology Cancer
    (S)-Velpatasvir- 13C,d3 ((S)-GS-5816- 13C,d3) is 13C labeled Velpatasvir. Velpatasvir (VEL, GS-5816) is a novel pan-genotypic hepatitis C virus (HCV) nonstructural protein 5A (NS5A) inhibitor with activity against genotype 1 (GT1) to GT6 HCV replicons. Velpatasvir is also a SARS-CoV 3CL pro inhibitor with an IC50 of 2.16 μM .
    (S)-Velpatasvir-13c,d3
  • HY-E70567
    Protease (Gly Cleaving)

    		Ser/Thr Protease Others
    Protease (Gly Cleaving) can be used to digest flexible linkers of fusion proteins composed of glycine or glycine and serine residues, repeating sequences, such as (Gly4Ser)n, GlyxSery (GS), and poly-glycine (G) linkers.
    Protease (Gly Cleaving)
  • HY-P1376A
    G-Protein antagonist peptide TFA
    1 Publications Verification

    		 mAChR Adrenergic Receptor Endocrinology
    G-Protein antagonist peptide TFA is a truncated substance P-related peptide, competes with receptor for G protein binding. G-Protein antagonist peptide TFA inhibits the activation of Gi or Go by M2 muscarinic cholinergic receptor (M2 mAChR) or of Gs by beta-adrenergic receptor in the reconstituted phospholipid vesicles, assayed by receptor-promoted GTP hydrolysis .
    G-Protein antagonist peptide TFA
  • HY-W394717
    BGC-20-1531

    PGN 1531

    		 Prostaglandin Receptor PKA Others
    BGC-20-1531 (PGN 1531), a benzenesulfonamide derivative, is a selective EP4 antagonist. BGC-20-1531 binds to PGE2 enhancing the ATPase activity, which are coupled to Gs proteins and thus activate adenylate cyclase generating cAMP and activating PKA. BGC-20-1531 is promising for research of liver disorders .
    BGC-20-1531
  • HY-149105
    FSH receptor antagonist 1

    		Estrogen Receptor/ERR Endocrinology
    FSH receptor antagonist 1 (compound 10) is a potent antagonist of the G(s)-protein-coupled human follicle-stimulating hormone (FSH) receptor. FSH receptor antagonist 1 exhibits an IC50 of 28 nM on a cell line expressing the human FSH receptor. FSH receptor antagonist 1 significantly inhibits follicle growth and ovulation in an ex vivo mouse model .
    FSH receptor antagonist 1
  • HY-151444
    LRRK2-IN-6

    		LRRK2 Neurological Disease
    LRRK2-IN-6 (compound 22) is a potent, orally active, selective leucine rich repeat protein kinase 2 gene (LRRK2) inhibitor with IC50 values of 4.6 and 49 μM for GS LRRK2 and WT LRRK2, respectively. LRRK2-IN-6 inhibits LRRK2 Ser1292 and Ser925 autophosphorylation. LRRK2-IN-6 can cross the blood-brain barrier .
    LRRK2-IN-6
  • HY-151441
    LRRK2-IN-5

    		LRRK2 Neurological Disease
    LRRK2-IN-5 (compound 25) is a potent, orally active, selective leucine rich repeat protein kinase 2 gene (LRRK2) inhibitor with IC50 values of 1.2 and 16 μM for GS LRRK2 and WT LRRK2, respectively. LRRK2-IN-5 inhibits LRRK2 Ser1292 and Ser925 autophosphorylation. LRRK2-IN-5 can cross the blood-brain barrier .
    LRRK2-IN-5
  • HY-N11141
    (R)-Octopamine

    		Adrenergic Receptor Others
    (R)-Octopamine is a Gs-coupled receptor agonist. (R)-Octopamine binds to the orthosteric site of BmOAR2 and interacts with the Asp115, Ser202 and Tyr300 residues to activate the receptor, which couples to Gs protein and thereby stimulates adenylate cyclase activity .
    (R)-Octopamine
  • HY-111964S1
    Lenacapavir-d5

    GS-6207-d5

    		 Isotope-Labeled Compounds HIV Infection
    Lenacapavir-d5 (GS-6207-d5) is the deuterium labeled Lenacapavir (HY-111964). Lenacapavir (GS-6207) is an HIV-1 capsid inhibitor. Lenacapavir binds to the interface between capsid hexamers and CA monomers, disrupts capsid assembly and viral maturation, inhibits nuclear translocation of HIV-1 DNA, interferes with CA-mediated protein-protein interactions, reduces the formation of 2-LTR circles and pre-integration proviruses, induces aberrant capsids, and decreases the production of mature HIV-1. Lenacapavir exhibits activity against a variety of HIV-1 subtypes and clinical isolates. Lenacapavir is applicable to research related to human immunodeficiency virus type 1 (HIV-1) infection .
    Lenacapavir-d5
  • HY-B1977
    Dipropetryn

    GS 16068; Sancap; Cotofor

    		 Herbicide Others
    Dipropetryn (GS 16068) is a compound that inhibits algal photosynthesis and toxin production. It can reduce the photosynthetic activity and pigment content of Karenia, reduce the levels of unsaturated fatty acids, reactive oxygen and hemolytic toxins, and regulate the expression of related proteins.
    Dipropetryn
  • HY-183761
    Antiviral agent 86

    		SARS-CoV Infection
    Antiviral agent 86 is an anti-coronavirus agent. Antiviral agent 86 acts as a binder of coronavirus non-structural protein 15 (nsp15), with a Ka value of 67 μM against human targets. Antiviral agent 86 inhibits the replication of HCoV-229E and SARS-CoV-2. Antiviral agent 86 exerts inhibitory effects at the post-entry lifecycle stage of coronaviruses in host cells and inhibits the formation of viral double-stranded RNA (dsRNA). Antiviral agent 86 exhibits an additive antiviral effect when used in combination with GS-441524. Antiviral agent 86 can be used in studies related to coronavirus infections .
    Antiviral agent 86
  • HY-145156
    CHU-128

    		GLP Receptor Metabolic Disease
    CHU-128 is an effective and selective GLP-1R agonist. CHU-128 exhibits strong signal specificity and can activate the Gs/cAMP pathway, but it cannot activate the Gq/calcium signal, ERK phosphorylation, or recruit β-inhibitory proteins. CHU-128 can be used for research on type 2 diabetes .
    CHU-128
  • HY-181984
    AGH-194

    		5-HT Receptor Neurological Disease
    AGH-194 is a 5-HT7 receptor agonist with a Ki value of 2 nM. AGH-194 activates Gs protein-coupled signaling pathways associated with neuroprotection and neurite outgrowth, and stimulates neurite outgrowth in neuronal cells. AGH-194 reduces cell damage in undifferentiated neuronal cells. AGH-194 can be used in the research of neurodegenerative diseases .
    AGH-194

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: